Neurodegenerative disease management

Keyphrases

Publications

2024

Hicham El Otmani, Mohamed Daghi, Nadia Tahiri Jouti, Suzanne Lesage
An overview of the worldwide distribution of LRRK2 mutations in Parkinson's disease. Neurodegenerative disease management (2024)
Michael R Haupts, Ute Essner, Mathias Mäurer
Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative disease management (2024)
Harald Hampel, Aya Elhage, Min Cho, James Ar Nicoll, Alireza Atri
Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary. Neurodegenerative disease management (2024)
Carrie M Hersh, Menglan Pang, Deborah M Miller, Marisa P McGinley, Megan Hyland, Tjalf Ziemssen, Robin L Avila
Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab. Neurodegenerative disease management (2024)
Mohammad Taheri, Ali Bahrami, Kiana Kimiaei Asadi, Mojdeh Mohammadi, Pejman Molaei, Mehrdad Hashemi, Fatemeh Nouri
A review on nonviral, nonbacterial infectious agents toxicity involved in neurodegenerative diseases. Neurodegenerative disease management (2024)
Paul Kamudoni, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Christian Henke, Dagmar Amtmann
Measuring fatigue in people with multiple sclerosis-which questionnaire should be used? A Plain Language Summary of Publication. Neurodegenerative disease management (2024)
Sachin G Nair, Elezabeth Koshy, Rajender Kandikonda, Sudheeran Kannoth
Refractory anti-NMDAR encephalitis with multiple nosocomial infections: optimizing the therapeutical options. Neurodegenerative disease management (2024)
Lauren Elizabeth Tueth, Ryan P Duncan, Beth E Crowner, Gammon M Earhart
Comparing balance using the BESTest in Alzheimer, Huntington and Parkinson disease. Neurodegenerative disease management (2024)
Philippe Huot
A discussion with Philippe Huot: the challenges of discovering novel therapies for the treatment of Parkinson's disease. Neurodegenerative disease management (2024)
Peter K Panegyres, Kerry L Lind, Cheryl A MacFarlane, Allana L Gurney
Medicinal cannabis in neurodegenerative disorders: an open label, dose finding, safety and efficacy study. Neurodegenerative disease management (2024)
Andrew J Larner, Alistair Burns
Free-Cog revisited: the diagnostic contribution of cognitive and executive function. Neurodegenerative disease management (2024)
Paul Kamudoni, Dagmar Amtmann, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Pavle Repovic, Kevin N Alschuler, Gloria von Geldern, Annette Wundes, Amy Barrett, Oyebimpe Olayinka-Amao, Christian Henke
People with multiple sclerosis help design a tool to measure physical functioning and how it affects their daily lives: a plain language summary. Neurodegenerative disease management (2024)
Kristin A Johnson, Victoria M Bandera, Manfred Diehl, Heather J Leach, Brett W Fling
Walking performance differs between people with multiple sclerosis who perform distinct types of exercise. Neurodegenerative disease management (2024)
Afra Paleel
Welcome to Volume 14 of Neurodegenerative Disease Management . Neurodegenerative disease management (2024)
Linda Lee, Loretta M Hillier, Tejal Patel, Stephanie K Lu, Michael Lee, Catherine Lee
An innovative approach to recruiting participants for dementia research: primary care and researcher perspectives. Neurodegenerative disease management (2024)
Harald Hampel, Aya Elhage, Min Cho, James Ar Nicoll, Alireza Atri
Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary. Neurodegenerative disease management (2024)
Melanie M Tidman, Dawn Reid White, Tim A White
Impact of a keto diet on symptoms of Parkinson's disease, biomarkers, depression, anxiety and quality of life: a longitudinal study. Neurodegenerative disease management (2024)
Shawn Maddaford, Philippe Huot
Glycine and clozapine: potential relevance for the treatment of Parkinson's disease. Neurodegenerative disease management (2024)

volume 14, number 1, 2024

Paul Kamudoni, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Christian Henke, Dagmar Amtmann
Measuring fatigue in people with multiple sclerosis - which questionnaire should be used? A Plain Language Summary of Publication. Neurodegenerative disease management 14 (1) (2024)
Michael R Haupts, Ute Essner, Mathias Mäurer
Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative disease management 14 (1) (2024)
Michael R Haupts, Ute Essner, Mathias Mäurer
Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative disease management 14 (1) (2024)
Paul Kamudoni, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Christian Henke, Dagmar Amtmann
Measuring fatigue in people with multiple sclerosis - which questionnaire should be used? A Plain Language Summary of Publication. Neurodegenerative disease management 14 (1) (2024)
Michael R Haupts, Ute Essner, Mathias Mäurer
Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative disease management 14 (1) (2024)
Michael R Haupts, Ute Essner, Mathias Mäurer
Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative disease management 14 (1) (2024)
Michael R Haupts, Ute Essner, Mathias Mäurer
Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Neurodegenerative disease management 14 (1) (2024)
Afra Paleel
Welcome to Volume 14 of Neurodegenerative Disease Management . Neurodegenerative disease management 14 (1) (2024)
Afra Paleel
Welcome to Volume 14 of Neurodegenerative Disease Management . Neurodegenerative disease management 14 (1) (2024)
Paul Kamudoni, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Christian Henke, Dagmar Amtmann
Measuring fatigue in people with multiple sclerosis - which questionnaire should be used? A Plain Language Summary of Publication. Neurodegenerative disease management 14 (1) (2024)

volume 14, number 2, 2024

Carrie M Hersh, Menglan Pang, Deborah M Miller, Marisa P McGinley, Megan Hyland, Tjalf Ziemssen, Robin L Avila
Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab. Neurodegenerative disease management 14 (2) (2024)
Peter K Panegyres, Kerry L Lind, Cheryl A MacFarlane, Allana L Gurney
Medicinal cannabis in neurodegenerative disorders: an open label, dose finding, safety and efficacy study. Neurodegenerative disease management 14 (2) (2024)

volume 13, number 6, 2024

Mohammad Taheri, Ali Bahrami, Kiana Kimiaei Asadi, Mojdeh Mohammadi, Pejman Molaei, Mehrdad Hashemi, Fatemeh Nouri
A review on nonviral, nonbacterial infectious agents toxicity involved in neurodegenerative diseases. Neurodegenerative disease management 13 (6) (2024)
Andrew J Larner, Alistair Burns
Free-Cog revisited: the diagnostic contribution of cognitive and executive function. Neurodegenerative disease management 13 (6) (2024)
Andrew J Larner, Alistair Burns
Free-Cog revisited: the diagnostic contribution of cognitive and executive function. Neurodegenerative disease management 13 (6) (2024)
Hicham El Otmani, Mohamed Daghi, Nadia Tahiri Jouti, Suzanne Lesage
An overview of the worldwide distribution of LRRK2 mutations in Parkinson's disease. Neurodegenerative disease management 13 (6) (2024)
Linda Lee, Loretta M Hillier, Tejal Patel, Stephanie K Lu, Michael Lee, Catherine Lee
An innovative approach to recruiting participants for dementia research: primary care and researcher perspectives. Neurodegenerative disease management 13 (6) (2024)
Hicham El Otmani, Mohamed Daghi, Nadia Tahiri Jouti, Suzanne Lesage
An overview of the worldwide distribution of LRRK2 mutations in Parkinson's disease. Neurodegenerative disease management 13 (6) (2024)
Linda Lee, Loretta M Hillier, Tejal Patel, Stephanie K Lu, Michael Lee, Catherine Lee
An innovative approach to recruiting participants for dementia research: primary care and researcher perspectives. Neurodegenerative disease management 13 (6) (2024)
Mohammad Taheri, Ali Bahrami, Kiana Kimiaei Asadi, Mojdeh Mohammadi, Pejman Molaei, Mehrdad Hashemi, Fatemeh Nouri
A review on nonviral, nonbacterial infectious agents toxicity involved in neurodegenerative diseases. Neurodegenerative disease management 13 (6) (2024)

2023

Emily Powell
Welcome to Volume 13 of Neurodegenerative Disease Management . Neurodegenerative disease management (2023)
Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L Masters, Min Cho, Lars Lannfelt, Jeffrey L Cummings, Andrea Vergallo
The amyloid-β pathway in Alzheimer's disease: a plain language summary. Neurodegenerative disease management (2023)
Kerstin Hellwig, Sandra Thiel, Sabrina Haben, Andrea I Ciplea, Anna Kurzeja
Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy. Neurodegenerative disease management (2023)
Lori M Bordenave, Corrine Fritcher Nelson, Becky G Farley, Tara L McIsaac
Impact of a 7-day retreat for people with Parkinson's disease: a phenomenological study. Neurodegenerative disease management (2023)
Charlotte Handberg, Ulla Werlauff
Cross-sectoral collaboration among hospital professionals on rehabilitation for patients with neuromuscular diseases. Neurodegenerative disease management (2023)
Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Aydemir, Laszlo Borsi, Elisabetta Verdun di Cantogno
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegenerative disease management (2023)
Moulika Mandal, Kashish Srivastava
Computerized cognitive testing in patients with Parkinson's disease: an Indian perspective. Neurodegenerative disease management (2023)
Tim Spelman, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson, Guy Laureys, Tomas Kalincik, Anneke Van Der Walt, Bassem Yamout, Jeannette Lechner-Scott, Aysun Soysal, Jens Kuhle, Jose Luis Sanchez-Menoyo, Yolanda Blanco Morgado, Daniele LA Spitaleri, Vincent van Pesch, Dana Horakova, Radek Ampapa, Francesco Patti, Richard Macdonell, Abdullah Al-Asmi, Oliver Gerlach, Jiwon Oh, Ayse Altintas, Namita Tundia, Schiffon L Wong, Helmut Butzkueven, null null
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. Neurodegenerative disease management (2023)
Caila B Vaughn, Katelyn S Kavak, Dejan Jakimovski, Natasha Qutab, Robin Avila, Megan Vignos, Bianca Weinstock-Guttman
Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon beta-1a users. Neurodegenerative disease management (2023)

volume 13, number 5, 2023